Medizinische Universität Graz - Research portal
Moik Florian |
Presentations at scientific and public conferences
Englisch, C.; Moik, F.; Steiner, D.; Berghoff, A.; Preusser, M.; Pabinger, I.; Ay, C.
Incidence and outcomes of bleeding events in patients with cancer: results from a prospective cohort study
GTH Congress 2024 – 68th Annual Meeting of the Society of Thrombosis and Haemostasis Research. 2024; 44(S01):S25-S26.-68th Annual Meeting of the Society of Thrombosis and Haemostasis Research; FEB 27 - MAR 1, 2024; Vienna, Austria.
[Oral Communication]
FullText
Englisch, C.; Moik, F.; Steiner, D.; Starzer, A.; Berghoff, A.; Preusser, M.; Pabinger, I.; Ay, C.
Thrombosis rates in patients with cancer receiving immune checkpoint inhibitors: results from a prospective cohort study
GTH Congress 2024 – 68th Annual Meeting of the Society of Thrombosis and Haemostasis Research. 2024; 44(S01):S26-S27.-68th Annual Meeting of the Society of Thrombosis and Haemostasis Research; FEB 27 - MAR 1, 2024; Vienna, Austria.
[Oral Communication]
FullText
Englisch, C; Moik, F; Steiner, D; Vladic, N; Starzer, A; Berghoff, A; Preusser, M; Pabinger, I; Ay, C
Incidence of venous and arterial thromboembolic events in patients with cancer receiving systemic anti-cancer therapies: results from a prospective cohort study
Research and Practice in Thrombosis and Haemostasis. Abstracts from the ISTH 2024 Congress, June 22–26, 2024, Bangkok.
. 2024; 8(S2):716--ISTH 2024 Congress; JUN 22-26, 2024; Bangkok, Thailand.
[Poster]
FullText
Englisch, C; Nopp, S; Moik, F; Starzer, A; Quehenberger, P; Preusser, P; Berghoff, A; Ay, C; Pabinger, I
The Vienna CATScore for predicting VTE risk in patients with cancer: an external validation across multiple time-points
Research and Practice in Thrombosis and Haemostasis. Abstracts from the ISTH 2024 Congress, June 22–26, 2024, Bangkok.. 2024; 8(S2):249-250.-ISTH 2024 Congress; JUN 22-26, 2024; Bangkok, Thailand.
[Oral Communication]
FullText
Englisch, C; Nopp, S; Pabinger, I; Moik, F; Steiner, D; Fritzer-Szekeres, M; Preusser, M; Berghoff, A; Ay, C
Growth differentiation factor-15 is associated with bleeding risk in patients with cancer: results from a prospective cohort
GTH Congress 2024 – 68th Annual Meeting of the Society of Thrombosis and Haemostasis Research. 2024; 44(S01):S29-S30.-68th Annual Meeting of the Society of Thrombosis and Haemostasis Research; FEB 27 - MAR 1, 2024; Vienna, Austria.
[Oral Communication]
FullText
Englisch, C; Nopp, S; Pabinger, I; Moik, F; Steiner, D; Starzer, A; Fritzer-Szekeres, M; Preusser, M; Berghoff, A; Ay, C
Growth differentiation factor-15 is associated with risk of major bleeding in patients with cancer: results from a prospective cohort study
Research and Practice in Thrombosis and Haemostasis. Abstracts from the ISTH 2024 Congress, June 22–26, 2024, Bangkok.. 2024; 8(S2):256--ISTH 2024 Congress; JUN 22-26, 2024; Bangkok, Thailand.
[Oral Communication]
FullText
Jonas, K; Riedl, JM; Steinlechner, SM; Moik, F; Jahn, S; Hasenleitner, S; Doleschal, B; Weiss, L; Seeber, A; Rumpold, H; Winder, T; Greil, R; Höfler, G; Gerger, A; Jost, P; Heitzer, E;
Low-level variants present a challenge in the clinical interpretation of liquid-biopsy-based comprehensive genomic profiling for patients with solid tumors
EACR Liquid Biopsies Conference; NOV 12-14, 2024; Lyon, FRANCE. 2024.
[Oral Communication]
Moik, F
SSC - Hemostasis and Malignancy
ISTH 2024 Congress; JUN 22-26, 2024; Bangkok, Thailand. 2024.
[Oral Communication]
Moik, F
Molekulares Tumorboard - Best Practice Klinik.
OeGHO- & AHOP-Frühjahrstagung 2024; APR 4-6, 2024; Vienna, Austria. 2024.
[Oral Communication]
Moik, F
Tissue Factor Pathway Inhibitor As Biomarker in Cancer Associated Thrombosis. Scientific Workshop on Interplay Between Coagulation and Malignancy
ASH 2024; DEC 7-10, 2024; San Diego, USA. 2024.
[Oral Communication]
Moik, F
Update on thrombosis risk in patients with malignancy – focus on novel anticancer therapies
68th Annual Meeting of the Society of Thrombosis and Haemostasis Research; FEB 27 - MAR 1, 2024; Vienna, Austria. 2024.
[Oral Communication]
Moik, F; Riedl, JM; Edlinger, L; Esterl, T; Hasenleithner, S; Kostmann, S; Cebular, L; Jahn, S; Kashofer, K; Zacharias, M; Hoefler, G; Heitzer, E; Gerger, A; Jost, PJ
Practice patterns and treatment outcomes of molecular tumour board (MTB)-based personalized cancer therapies: A single-center experience
ANN ONCOL. 2024; 35: S262-S263.
Doi: 10.1016/j.annonc.2024.08.130
Web of Science
FullText
FullText_MUG
Moik, F; Riedl, JM; Edlinger, L; Esterl, T; Hasenleithner, S; Kostmann, S; Cebular, L; Jahn, S; Kashofer, K; Zacharias, M; Hoefler, G; Heitzer, E; Gerger, A; Jost, PJ
122P - Practice patterns and treatment outcomes of molecular tumour board (MTB)-based personalized cancer therapies: A single-center experience
Annals of Oncology. Abstract Book of the ESMO Congress 2024, 13-17 September 2024. . 2024; 35(S2):262-263.-ESMO 2024; SEP 13-17, 2024; Barcelona, Spain.
[Poster]
FullText
Seeber, A; Huemer, F; Doleschal, B; Taghizadeh, H; Reimann, P; Moik, F; Kostmann, S; Wagner, L; Granitzer, J; Hamid, MA; Bachleitner, C; Amann, A; Wolf, D; Greil, R; Jost, PJ; Winder, T; Rumpold, H; Weiss, L; Gerger, A; Riedl, JM
Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study
ANN ONCOL. 2024; 35: S445-S446.
Doi: 10.1016/j.annonc.2024.08.599
Web of Science
FullText
FullText_MUG
Seeber, A; Huemer, F; Doleschal, B; Taghizadeh, H; Reimann, P; Moik, F; Kostmann, S; Wagner, L; Granitzer, L; Abdel Hamid, M; Bachleitner, C; Amann, A; Wolf, D; Greil, R; Jost, PJ; Winder, T; Rumpold, H; Weiss, L; Gerger, A; Riedl, JM
530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study
Annals of Oncology. Abstract Book of the ESMO Congress 2024, 13-17 September 2024. . 2024; 35(S2):445-446.-ESMO 2024; SEP 13-17, 2024; Barcelona, Spain.
[Poster]
FullText
Vladic, N; Englisch, C; Moik, F; Berghoff, A; Preusser, M; Pabinger, I; Ay, C
Performance of established risk assessment models for the prediction of VTE in patients with cancer receiving systemic anticancer therapies – results from a contemporary perspective cohort study
Research and Practice in Thrombosis and Haemostasis. Abstracts from the ISTH 2024 Congress, June 22–26, 2024, Bangkok.. 2024; 8(S2):723--ISTH 2024 Congress; JUN 22-26, 2024; Bangkok, Thailand.
[Poster]
FullText
Barth, D; Moik, F; Steinlechner, SM; Posch, F; Schlintl, V; Koch, L; John, N; Wurm, R; Pichler, M; Bauernhofer, T; Reimann, P; Wohlkönig, C; Richtig, E; Winder, T; Preusser, M; Jost, PJ; Ay, C; Gerger, A; Terbuch, A; Riedl, JM
Early kinetics of C-reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: A multi-center cohort study
ANN ONCOL. 2023; 34: S259-S259.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Barcelona, SPAIN.
Doi: 10.1016/j.annonc.2023.09.2917
[Poster]
Web of Science
FullText
FullText_MUG
C Englisch , F Moik , J Thaler , S Koder , M Preusser , I Pabinger , C Ay
Tissue Factor Pathway Inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer
GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research. 2023; 43(S01):S23--67th Annual Meeting of the Society of Thrombosis and Haemostasis Research; Feb 21-24, 2023; Frankfurt, Germany.
[Oral Communication]
FullText
Englisch, C; Moik, F; Thaler, J; Koder, S; Preusser, M; Pabinger, I; Ay, C
Tissue Factor Pathway Inhibitor is Associated with Risk of Venous Thromboembolism and All-Cause Mortality in Patients with Cancer
Abstracts from the ISTH 2023 Congress. 2023; 7(S2):232-233.-ISTH 2023 Congress; JUN 24–28, 2023; Montreal, Canada.
[Oral Communication]
FullText
F Moik , S Kraler , F Montecucco , L Liberale , S Nopp , C Englisch , T Lapikova-Bryhinska , A Akhmedov , A von Eckardstein , F Wenzl , I Pabinger , T Lüscher , C Ay
Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer
GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research. 2023; 44(S01):S23-S24.-67th Annual Meeting of the Society of Thrombosis and Haemostasis Research; Feb 21-24, 2023; Frankfurt, Germany.
[Oral Communication]
FullText
Nopp, S; Moik, F; Kraler, S; Englisch, C; Preusser, M; von Eckardstein, A; Pabinger, I; Lüscher, T; Ay C
Association of Growth Differentiation Factor-15 (GDF-15) with Thromboembolism and Mortality in Patients with Cancer: Findings from the Vienna CATS Study
Abstracts from the ISTH 2023 Congress. 2023; 7(S2):231-232.-ISTH 2023 Congress; JUN 24–28, 2023; Montreal, Canada.
[Oral Communication]
FullText
Riedl, JM; Steinlechner, SM; Moik, F; Heitzer, E; Jahn, S; Hasenleithner, S; Doleschal, B; Weiss, L; Seeber, A; Rumpold, H; Winder, T; Greil, R; Jost, PJ; Hoefler, G; Speicher, M; Gerger, A
SOUND: A phase II trial evaluating the efficacy of molecular profiling of circulating ± tumor tissue DNA for salvagetherapy matching in patients with advanced and refractory carcinoma
ANN ONCOL. 2023; 34: S1186-S1186.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Barcelona, SPAIN.
Doi: 10.1016/j.annonc.2023.09.1349
[Poster]
Web of Science
FullText
FullText_MUG
Englisch, C; Konigsbrugge, O; Moik, F; Quehenberger, P; Preusser, M; Pabinger, I; Ay, C
Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer
THROMB RES. 2022; 213: S12-S12.-11th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC); MAY 27-29, 2022; Bergamo, ITALY.
[Oral Communication]
Web of Science
Moik, F
Extracellular Vesicle TF Activity and Mortality in Pancreatic Cancer (Scientific Workshop on Interplay between Coagulation and Malignancy)
64th ASH Annual Meeting; DEC 10-13, 2022; New Orleans, USA. 2022.
[Oral Communication]
Moik, F; Kraler, S; Montecucco, F; Liberale, L; Nopp, S; Englisch, C; Lapikova-Bryhinska, T; Akhmedov, A; von Eckardstein, A; Wenzl, FA; Pabinger, I; Luscher, TF; Ay, C
Cardiovascular Biomarkers for the Prediction of Adverse Cardiovascular Events and Mortality in Patients with Cancer
BLOOD. 2022; 140: 1255-1256.
Doi: 10.1182/blood-2022-163287
[Oral Communication]
Web of Science
FullText
FullText_MUG
Moik, F; Riedl, J; Barth, D; Chan, WSE; Wiedemann, S; Holler, C; Fuereder, T; Jost, P; Pabinger, I; Preusser, M; Ay, C
Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors
BLOOD. 2022; 140: 1250-1251.
Doi: 10.1182/blood-2022-160087
[Oral Communication]
Web of Science
FullText
FullText_MUG
Riedl, JM; Barth, D; Steinlechner, S; Moik, F; Posch, F; Schlintl, V; Mayer, MC; Sandner, AM; Berton, F; Koch, L; John, N; Wurm, R; Pichler, M; Absenger, G; Jost, PJ; Wohlkonig, C; Richtig, E; Winder, T; Gerger, A; Terbuch, A
Early CRP Kinetics after Initiation of Immune Checkpoint Inhibitors is a predictive Biomarker for Treatment Response independent of the Tumor Antity
ONCOL RES TREAT. 2022; 45(SUPPL 2):228-228.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien.
[Poster]
Web of Science
Troelsen, FS; Vago, EK; Horvath-Puho, E; van Es, N; Mulder, FI; Moik, F; Erichsen, R; Ay, C; Sorensen, HT
KRAS mutation in colorectal cancer and risk of venous thromboembolism: a Danish population-based cohort study
THROMB RES. 2022; 213: S11-S11.-11th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC); MAY 27-29, 2022; Bergamo, ITALY.
[Oral Communication]
Web of Science
Moik, F
Immuntherapie und Thrombose bei onkologischen Patienten
OeGHO- & AHOP-Frühjahrstagung 2021; APR 8-10, 2021; Wien. 2021.
[Onlinepräsentation]
Moik, F; Ay, C; Horváth-Puhó, E; Pabinger, I; Mulder, F; van Es, N; Sørensen, HT
Risk of Venous and Arterial Thromboembolic Events in Patients Receiving Targeted Anti-cancer Therapy – A Nationwide Cohort Study.
Research and Practice in Thrombosis and Haemostasis. 2021; 5(e12591):-Congress of the International Society of Thrombosis and Haemostasis (ISTH) 2021; JUL 17–21, 2021; Philadelphia, USA.
[Oral Communication]
FullText
Moik, F; van Es, N; Posch, F; Di Nisio, M; Fureder, T; Preusser, M; Pabinger, I; Ay, C
Evaluation of gemcitabine and platinum agents for the prediction of venous thromboembolism in patients with cancer: results from the Vienna Cancer and thrombosis Study
THROMB RES. 2021; 200: S68-S69.
[Poster]
Web of Science
FullText
Starzer, AM; Mayer, J; Haselboeck, H; Kreminger, J; Berger, J; Moik, F; Goerzer, I; Preusser, M; Puchhammer, E; Berghoff, AS
Exploration of torque teno virus (TTV) levels as marker for immune suppression during systemic therapy in advanced solid cancer patients.
Annals of Oncology. 2021; 32, Supplement 5: S1216--ESMO CONGRESS 2021; SEP 16-21, 2020; Paris, France. .
[Poster]
FullText
Mauracher, LM; Krall, M; Moik, F; Hell, L; Roiß, J; Hofbauer, TM; Brostjan, C; Ay, C; Pabinger, I
Increased Potential of Neutrophil Activation and Neutrophil Extracellular Trap Formation in Patients with Lung Cancer
Research and Practice in Thrombosis and Haemostasis. 2020; 4(S1):-ISTH 2020 Virtual Congress of the International Society on Thrombosis and Haemostasis; JUL 12-14, 2020; Milano, Italy;.
[Poster]
FullText
Moik, F; Chan, WSE; Wiedemann, S; Höller, C; Tuchmann, F; Aretin, MB; Fuereder, T; Zöchbauer-Müller, S; Preusser, M; Pabinger, I; Ay, C
Incidence, Risk Factors and Clinical Outcome of Venous and Arterial Thromboembolic Events in Patients Treated with Immune-checkpoint Inhibitors: A Single-center Cohort Study
Research and Practice in Thrombosis and Haemostasis. 2020; 3(S1):-ISTH 2020 Virtual Congress of the International Society on Thrombosis and Haemostasis; JUL 12-14, 2020; Milano, Italy;.
[Poster]
FullText
Moik, F; Chan, WSE; Wiedemann, S; Höller, C; Tuchmann, F; Aretin, MB; Füreder, T; Zöchbauer-Müller, S; Preusser, M; Pabinger, I; Ay, C
Incidence, risk factors and clinical outcome of venous and arterial thromboembolism in patients treated with immune-checkpoint inhibitors.
Annals of Oncology. 2020; 31 (Supplement 4): S1051-S1052.-ESMO Virtual Congress 2020; SEP 19-21, 2020; Lugano, Switzerland..
[Poster]
FullText
Moik, F; Prager, G; Wiedemann, S; Posch, F; Pabinger, I; Ay, C.
Biomarkers of Haemostasis and Occurrence of Venous Thromboembolism Are Associated with Disease Progression and Poor Prognosis in Patients with Pancreatic Cancer.
Blood. 2020; 136 (Supplement 1): 7-8.-American Society of Hematology (ASH) 2020 Annual Meeting; DEC 5-8, 2020; San Diego, USA.
[Oral Communication]
FullText
Moik, F; Zöchbauer-Müller, S; Pabinger, I; Ay, C;
Biomarkers of haemostasis predict response to chemotherapy in patients with advanced lung cancer
Society of Thrombosis and Haemostasis Research (GTH) 64th Annual Meeting; FEB 18-21, 2020; Bremen, Germany;. 2020.
[Oral Communication]
Moik, F; Zöchbauer-Müller, S; Posch, F; Pabinger, I; Ay, C
Systemic infammation and activation of haemostasis predict response to chemotherapy and poor prognosis in patients with advanced lung cancer
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology. memo. 2020; 13: 23-65.-Frühjahrstagung 2020 der Österreichischen Gesellschaft für Hämatologie und Medizinische Onkologie (ÖGHO); MAR 19-21, 2020; Vienna, Austria.
[Poster]
FullText
Nopp, S; Klok, FA; Moik, F; Petrovic, F; Derka, I; Ay, C; Zwick, RH
Improvements in Short- and Long-term Outcomes in Patients with Pulmonary Embolism after Outpatient Pulmonary Rehabilitation
Research and Practice in Thrombosis and Haemostasis. 2020; 3(S1):-ISTH 2020 Virtual Congress of the International Society on Thrombosis and Haemostasis; JUL 12-14, 2020; Milano, Italy;.
[Poster]
FullText
Nopp, S; Moik, F; Petrovic, M; Derka, I; Ay, C; Zwick, RH
Improvements in exercise capacity and inspiratory muscle strength in patients with pulmonary embolism after outpatient pulmonary rehabilitation
Society of Thrombosis and Haemostasis Research (GTH) 64th Annual Meeting; FEB 18-21, 2020; Bremen, Germany;. 2020.
[Poster]
Riedl, J; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Schaberl-Moser, R; Stotz, M; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nab-Paclitaxel as palliative first-line treatment of advanced pancreatic cancer: An Austrian observational Tri-Center comparative effectiveness analysis.
ONCOL RES TREAT. 2020; 43(SUPPL 4):215-215.
[Poster]
Web of Science
Riedl, JM; Posch, F; Gantschnigg, A; Horvath, L; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nabPaclitaxel as First-line palliative Therapy in advanced Pancreatic Cancer: a Propensity-Score Analysis.
WIEN KLIN WOCHENSCHR. Abstracts 51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin. 2020; 132(SUPPL 2):78-79.-51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; SEP 24-26, 2020; Salzburg, AUSTRIA.
[Poster]
Web of Science
Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
ANN ONCOL. 2020; 31: S942-S942.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2013
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Schwarzenbacher, E; Moik, F; Horvath, L; Renneberg, F; Posch, F; Barth, D; Gantschnigg, A; Schaberl-Moser, R; Pichler, M; Stotz, M; Stoger, H; Ay, C; Greil, R; Gerger, A; Djanani, A; Schlick, K; Riedl, J
Incidence, prediction and outcome of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of Gemcitabine/nab-Paclitxel or FOLFIRINOX.
ONCOL RES TREAT. 2020; 43(SUPPL 4):214-214.
[Poster]
Web of Science
Schwarzenbacher, E; Moik, F; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Ay, C; Stoger, H; Greil, R; Djanani, A; Gerger, A; Schlick, K; Riedl, JM
Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX.
ANN ONCOL. 2020; 31: S949-S950.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2035
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Starzer, AM; Kreminger, J; Berger, JM; Moik, F; Rauchwarter, M; Mayer, J; Haselboeck, H; Heller, G; Preusser, M; Berghoff, AS
Fatigue changes according to systemic therapy type in patients with advanced solid cancer.
Annals of Oncology. 2020; 31 (Supplement 4): S1069--ESMO VIRTUAL CONGRESS 2020; SEP 19-21, 2020; Lugano, Switzerland..
[Poster]
FullText
Glantschnig, T; Posch, F; Firla, S; Moik, F; Ablasser, K; Binder, JS; Stoschitzky, G; Wallner, M; Von Lewinski, D; Stoger, H; Zirlik, A; Pichler, M; Rainer, PP
Clinical utility of echocardiographic left-ventricular ejection fraction monitoring for cardiotoxicity risk assessment in patients with HER2+early breast cancer undergoing trastuzumab-based therapy
WIEN KLIN WOCHENSCHR. 2019; 131: 292-293.
[Poster]
Web of Science
Moik, F; Posch, F; Grilz, E; Scheithauer, W; Pabinger, I; Prager, G; Ay, C
Haemostatic biomarkers predict risk of mortality and overall survival
in patients with metastatic colorectal cancer
Frühjahrstagung der Österreichischen Gesellschaft für
Hämatologie und Medizinische Onkologie (OeGHO) 2019; APR 11-13, 2019; Linz, Austria;. 2019.
[Poster]
Moik, F; Posch, F; Grilz, E; Scheithauer, W; Pabinger, I; Prager, G; Ay, C
Haemostatic Biomarkers for Prediction of Therapy Response and Prognosis of Disease in Patients with Metastatic Colorectal Cancer.
Research and Practice in Thrombosis and Haemostasis. 2019; 3(S1):187-188.-Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2019; JUL 6-10, 2019; Melbourne, Australia;.
[Oral Communication]
FullText
Pondorfer, P; Mollnar, S; Kasparek A; Reinisch, S; Moik, F; Stolz, M; Halm, M; Szkandera, J; Gerger; A; Kapp, K; Partl, R; Vasicek, S; Weiland, T; Pichler, M; Störer, H; Posch, F; Thurnher, D;
Induction chemotherapy and chemoradiation for patients with advanced HNSCC: A systematic analysis of acute treatment toxicities and their management
https://www.hno.at/fileadmin/userdaten/HNO_Kongress_2019/HNO2019_Abstractband_web_20190828.pdf. 2019; -Österreichischer HNO Kongress; Sep 11-15, 2019; Salzburg.
[Oral Communication]
FullText
Pondorfer, P; Molnar, S Kasparek, A.-K.; Reinisch, S; Moik, F; Stotz, M; Halm, M; Szkandera, J; Berger, A; Kapp, K.S;
Vasicek, S; Weiland, T; Pichler, M; Störer, H; Posch, F; Thurnher, D;
HPV infection as a predictive biomarker for response to induction chemotherapy and concomitant chemoradiation in patients with advanced head and neck squamous cell carcinoma
CEORL HNS; JUN 30, 2019; Brussels. 2019.
[Oral Communication]
FullText
Posch, F; Glantschnig, T; Firla, S; Smolle, M; Balic, M; Moik, F; Stoeger, H; Zirlik, A; Pichler, M; Rainer, P
Clinical utility of echocardiographic left-ventricular ejection fraction monitoring for cardiotoxicity risk assessment in patients with HER2+early breast cancer undergoing trastuzumab-based therapy
EUR HEART J. 2019; 40: 3844-3844.-ESC Congress / World Congress of Cardiology; AUG 31-SEP 04, 2019; Paris, FRANCE.
[Poster]
Web of Science
Reicher, A; Prinz, F; Klec, C; Stoeger, H; Moik, F; Posch, F; Pichler, M
Characterization of the fundamental role of fibroblast growth factor receptor 2 (FGFR2) gene fusions in carcinogenesis of intrahepatic cholangiocarcinoma using CRISPR/Cas9 genome engineering.
OEGHO- & AHOP-Frühjahrstagung 2019. 2019; -OeGHO- & AHOP-Frühjahrstagung 2019; 11.-13.April, 2019; Linz, AUSTRIA.
[Poster]
Klöckl, MC; Kasparek, AK; Riedl, J; Moik ,F; Mollnar, S; Stotz, M; Szkandera, J; Terbuch, A; Gerger, A; Niedrist, T; Pichler, M; Bauernhofer T; Stöger H; Posch, F
Estimated versus measured glomerular filtration rate to
evaluate kidney function in patients with cancer undergoing
cisplatin-based chemotherapy
Oncology Research
and Treatment . 2018; 41(Suppl4):224-224.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; SEP 28- OCT 2, 2018; Vienna, AUSTRIA. (ISBN: 978-3-318-06425-4 )
[Poster]
Web of Science
FullText
Mollnar, S; Pondorfer, P; Reinisch, S; Moik, F; Halm, M; Kasparek, AK; Klockl, MC; Stotz, M; Szkandera, J; Gerger, A; Vasicek, S; Weiland, T; Pichler, M; Stoger, H; Thurnher, D; Posch, F
Definitive chemoradiotherapy with or without induction chemotherapy for unresectable squamous cell carcinoma of the head & neck: a propensity-score analysis
ONCOL RES TREAT. 2018; 41: 248-248.
[Poster]
Web of Science